Table 3 Comparison of medications between patients with MDA5+DM in the survival and non-survival groups

Glucocorticoids only

12 (37.5)

16 (17.0)

0.016

Dual therapy

16 (50.0)

58 (61.7)

0.245

 Glucocorticoids + tacrolimus

5 (15.6)

31 (33.0)

0.061

 Glucocorticoids + intravenous cyclophosphamide

7 (21.9)

24 (25.5)

0.678

 Glucocorticoids + mycophenolate mofetil

1 (3.1)

1 (1.1)

1.000

 Glucocorticoids + cyclosporine A

2 (5.9)

2 (2.1)

0.615

 Glucocorticoids + thalidomide

1 (3.1)

0 (0)

0.254

Triple therapy

4 (12.5)

20 (21.3)

0.275

Intravenous pulse methylprednisolone

7 (21.9)

6 (6.4)

0.013

Rituximab

2 (6.3)

1 (1.1)

0.322

Tocilizumab

2 (6.3)

1 (1.1)

0.322

Tofacitinib

0 (0)

9 (9.6)

0.110

Intravenous immunoglobulin

21 (65.5)

40 (42.6)

0.024